

Product Name : PZM21

Synonyms : PZM21; PZM-21; PZM 21

Cat No. : M18199

CAS Number : 1997387-43-5

Molecular Formula : C19H27N3O2S

Formula Weight : 361.5

Chemical Name : 1-[(2S)-2-(Dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-[(2S)-1-(thiophen-3-yl)propan-2-yl]urea

PZM21 is a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment. PZM21 is an experimental opioid analgesic drug that is being researched for the treatment of pain. It is a functionally selective μ-opioid receptor agonist which produces μ-opioid receptor mediated G protein signaling, with potency and efficacy similar to

Description

The discreption agonist which produces proposed receptor mediated 3 protein signating, with potency and emicacy similar to morphine, but with less β-arrestin 2 recruitment. In tests on mice, PZM21 was slightly less potent than morphine or TRV130

as an analgesic, but also had significantly reduced adverse effects, with less constipation than morphine, and very little

respiratory depression, even at high doses.

Pathway : Others

Target : Other Targets

Receptor : μ-opioid receptor

Solubility : DMSO : ≥ 72 mg/mL; 199.17 mM

SMILES : Oc1ccc(cc1)C[C@@H](CNC(=O)N[C@@H](C)Cc2ccsc2)N(C)C

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Manglik A, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016 Sep 8;537(7619):185-190.